New England Life Care, Inc., Portland, ME
Is New England Life Care, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does New England Life Care, Inc. hold a Maine pharmacy license?
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records.
Has New England Life Care, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Oct 8, 2019) and 1 FMD-145 letter (Oct 8, 2019) for New England Life Care, Inc. State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- New England Life Care, Inc.
- Location
- Portland, ME
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Oct 8, 2019
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 5 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as New England Life Care, Inc., a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Oct 8, 2019 | State referral letter | State Referral Letter Issued 10/08/2019 | Not linked by FDA |
| Oct 8, 2019 | FMD-145 letter | FMD-145 Letter Issued 10/08/2019 | Not linked by FDA |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists New England Life Care, Inc., Portland, ME (FEI number 1000159373), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 2, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 1000159373 | 1043176 |
Form 483s FDA has published for this site
- Apr 9, 2018: Form 483 to New England Life Care, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 26, 2018 to Mar 2, 2018: 5 observations
- Firm on the cover
- New England Life Care, I nc., 108a I ndustrial Way, Portl a nd, ME 04103-1082 Producer of Sterile Drug Products
- FEI number
- 1000159373
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.
Specifically:
The following observations relate to inadequate qualification, operatio, and maintenance o f ISO 5 classified <Redacted B4> la mi nar flow hoods <Redacted B4> and biological safety cabinet used to produce sterile drugs for human use:
A. ISO 5 classified areas were not certified under dynamic conditions. Specifically, uni-directional airflow was not verified under operational conditions in dynamic airflow pattern studies in ISO 5 <Redac ted B4> laminar flo w hoods <Redacted B4> and biological safety c abinet <Redacted B4> used to produce sterile drugs for human use.
B. Your aseptic simulation (nedia fill) program is not designed to include performance in each ISO
5 laminar flow hood <Redacted B4> used for production and filling of sterile drug s and aseptic simulations are never performed in the ISO 5 biosafety cabinet <Redacted B 4> used to process and fill cytotoxic drugs.
C. ...
Observation 2
You produced beta-lactam drugs without providing adequate containment, segregation and cleaning of work surfaces to prevent cross-contamination.
Specifically:
Your cleanroom design and operational procedures do not provide adequate containment and segregation of Beta-Lactam antibiotic products from general dru gs produced. Beta-Lactam antibiotics are routinely pro cessed in the same laminar flow hoods <Redacted B4> as other general drug products separate d only by a wipe down of hood surfaces with sterile <Redacted B4>. For example:
On 02/27/2018 I observed a Pharmacy Technician process RX <Redacte d B6> Oxacillin Sodi um in laminar flow hood <Redacted B4>. According to your records the nex t order pr ocessed in hood <Redacted B4> was a TPN for RX# <Redacted B6>
Furthermore, you do not have a specific process to deactivate and remove any Beta-Lactam product spillage that may occur within the laminar flow hoods or facil ity during handling, processing, or filling operations.
Observation 3
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically:
DATE I SSUED
You do not sanitize drug product components and process equipment stored in the ISO 7 classified buffer area immediately before entry to the ISO 5 laminar flow hoods. For example:
On 02/26/2018 and 02/27/2018 I observed numerous times that components stored in the ISO-7 cle anroom including <R edacted B4> and process requipment including syrin ges were not sanitized immediately before placing them, still in the outer wrapping, into ISO 5 laminar flow hoods.
Observation 4
Personnel engaged in aseptic processing were observed with exposed hair.
Specifically:
On 02/26-28/2018 I observed numerous times that Pharmacy Technician 's faces, heads, and shoulders entered the plane of ISO 5 laminar flow hoods during production operations and cleaning. Technicians are not required to wear goggles or glasses so the face and forehead is exposed above the dust mask.
Observation 5
Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically:
Commercial cleaning and disinfection agents used within ISO 5 classified <Redacted B4> lamin ar flow hoods <Redacted B4> and biologi cal safety cabinet <Redacted B4> used to produce st erile drugs for human use are not claimed to be sterile. For example:
The labeling provided for <Redacted B4> does not claim sterility <Red
acted B4> is <Redacted B4> and applied with non-sterile wipes for daily cleaning and disinfection o f surfaces inside the ISO 5 hoods and biological safety cabinet.
<Redacte d B4> is directly applied with non-sterile wipes for <Redacted B4> cleaning and disinfection of surfaces inside the ISO 5 hoods and biological safety cabinet.
Furthermore, you do not provide sufficient disinfection agent contact (dwell) time on surfaces within the ISO 5 classified < Redacted B4> lamin ar flow hoods <Redacted B4> an d bi ological safety cabinet <Redacted B4>. The manufacturer's directions for use of <Redacted B4>
indicate that the minimum effecti ve contact time is <Redacted B4> and manufacturer's directions for <Redacted B4> specify a <Redacted B4> ...
State board of pharmacy records
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.